Shire & Baxalta Seal The Deal

Shire PLC and Baxalta Inc. shareholders have both voted in favor of the latter's sale to rare disease focused Shire for a price tag of $32bn – closing an almost year-long deal discussion.

Both companies held general meetings on May 27 to vote on the proposed merger that will see Baxalta stockholders, who were initially reticent of a merger arrangement, receive $18.00 in cash and 0.1482 Shire ADS per Baxalta share – the deal agreed back in January 2016.

Shire CEO Dr. Flemming Ornskov said in a statement, "[We are] grateful that our shareholders have voiced their support by...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip